The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China

被引：0
|
作者：
Shuyan Gu
Jinghong Gu
Xiaoyong Wang
Xiaoling Wang
Lu Li
Hai Gu
Biao Xu
机构：
[1] Nanjing University,Center for Health Policy and Management Studies, School of Government
[2] University of Washington,Department of Economics
[3] Shandong Provincial Hospital Affiliated to Shandong First Medical University,Health Insurance Office
[4] Shanghai Jiao Tong University School of Medicine,Department of Endocrinology, Xinhua Hospital
[5] First Affiliated Hospital of Dalian Medical University,Department of Pharmacy
来源：
Health Economics Review | / 14卷
关键词：
Cost-effectiveness; Semaglutide; Sitagliptin; Type 2 diabetes; China;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] ONCE-WEEKLY SEMAGLUTIDE VERSUS DULAGLUTIDE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN PORTUGAL: A LONG-TERM COST-EFFECTIVENESS ANALYSIS BASED ON SUSTAIN 7
    Malkin, S. J.
    Belbute, D. G.
    Hunt, B.
    Hoxer, C. S.
    Martin, V
    VALUE IN HEALTH, 2018, 21 : S129 - S129
  • [22] COST-EFFECTIVENESS ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN MEXICO
    Valdez-Huerta, R.
    Moreno, D.
    Hernandez, Paladio J. A.
    VALUE IN HEALTH, 2022, 25 (07) : S429 - S429
  • [23] Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
    Hunt, Barnaby
    Malkin, Samuel J. P.
    Moes, Robert G. J.
    Huisman, Eline L.
    Vandebrouck, Tom
    Wolffenbuttel, Bruce H. R.
    BMJ OPEN DIABETES RESEARCH & CARE, 2019, 7 (01)
  • [24] A Long-term Cost-Effectiveness Analysis of Treatments for Type 2 Diabetes in Portugal: Once-Weekly Semaglutide 1 mg Versus Once-Daily Empagliflozin 25 mg
    Carvalho, Davide
    Costa, Catarina
    Hallen, Nino
    Baker-Knight, James
    Hunt, Barnaby
    REVISTA PORTUGUESA DE ENDOCRINOLOGIA DIABETES E METABOLISMO, 2021, 16 (1-2) : 13 - 20
  • [25] A LONG-TERM COST-EFFECTIVENESS ANALYSIS OF TREATMENTS FOR TYPE 2 DIABETES IN PORTUGAL: ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS ONCE-DAILY EMPAGLIFLOZIN 25 MG
    Hallen, N.
    Carvalho, D.
    Costa, C.
    Hunt, B.
    VALUE IN HEALTH, 2020, 23 : S510 - S510
  • [26] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Ataru Igarashi
    Barnaby Hunt
    Lars Wilkinson
    Jakob Langer
    Richard F. Pollock
    Advances in Therapy, 2020, 37 : 4446 - 4457
  • [27] Lower Drug Cost of Successfully Treating Patients with Type 2 Diabetes to Targets with Once-Weekly Semaglutide versus Once-weekly Dulaglutide in Japan: A Short-Term Cost-Effectiveness Analysis
    Igarashi, Ataru
    Hunt, Barnaby
    Wilkinson, Lars
    Langer, Jakob
    Pollock, Richard F.
    ADVANCES IN THERAPY, 2020, 37 (10) : 4446 - 4457
  • [28] Cost-effectiveness of once-weekly semaglutide versus empagliflozin in people with type 2 diabetes and inadequate glycaemic control in Sweden
    Londahl, M.
    Nihlberg, K.
    Ericsson, A.
    DIABETOLOGIA, 2019, 62 : S399 - S399
  • [29] Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden
    Ericsson, Asa
    Fridhammar, Adam
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (10) : 997 - 1005
  • [30] LONG-TERM COST-EFFECTIVENESS ANALYSES OF ONCE-WEEKLY SEMAGLUTIDE 1 MG VERSUS EMPAGLIFLOZIN 25 MG FOR TREATMENT OF TYPE 2 DIABETES IN THREE COUNTRIES: BOSNIA AND HERZEGOVINA, GREECE, AND SLOVENIA
    Hallen, N.
    Djekic, D.
    Ioannidis, I.
    Liatis, S.
    Lapajne, Ogric A.
    Thanopoulou, A.
    Hunt, B.
    VALUE IN HEALTH, 2020, 23 : S511 - S511
12345